TY - CHAP
T1 - The Pathophysiology of Cardiac Hypertrophy and Heart Failure
AU - Stansfield, William E.
AU - Ranek, Mark
AU - Pendse, Avani
AU - Schisler, Jonathan C.
AU - Wang, Shaobin
AU - Pulinilkunnil, Thomas
AU - Willis, Monte S.
PY - 2014/1
Y1 - 2014/1
N2 - Left ventricular hypertrophy (LVH) is one of the most common cardiovascular diseases; the estimated prevalence is 20% in the general population. In spite of being one of the greatest independent risk factors for cardiovascular morbidity and mortality, it remains essentially untreated. In this chapter, we review the complex interplay of physiologic systems that give rise to pathologic hypertrophy and heart failure. We explore the hierarchy of intra- and intercellular signaling systems that converge to produce the hypertrophic phenotype. Lastly, we consider novel access points within these systems that may represent new therapeutic windows for pharmacologic intervention.
AB - Left ventricular hypertrophy (LVH) is one of the most common cardiovascular diseases; the estimated prevalence is 20% in the general population. In spite of being one of the greatest independent risk factors for cardiovascular morbidity and mortality, it remains essentially untreated. In this chapter, we review the complex interplay of physiologic systems that give rise to pathologic hypertrophy and heart failure. We explore the hierarchy of intra- and intercellular signaling systems that converge to produce the hypertrophic phenotype. Lastly, we consider novel access points within these systems that may represent new therapeutic windows for pharmacologic intervention.
UR - http://www.scopus.com/inward/record.url?scp=84902749129&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902749129&partnerID=8YFLogxK
U2 - 10.1016/B978-0-12-405206-2.00004-1
DO - 10.1016/B978-0-12-405206-2.00004-1
M3 - Chapter
AN - SCOPUS:84902749129
SN - 9780124052062
SP - 51
EP - 78
BT - Cellular and Molecular Pathobiology of Cardiovascular Disease
PB - Elsevier Inc.
ER -